The glial fibrillary acidic protein (GFAP) staining revealed reactive gliosis in 56.3% of COVID-19 patients (9/16) in contrast to controls (40%, 2/6) (Fig. 2i–l). The gene discussed is GFAP; the disease is COVID-19.